LAUSR

Incretin contains two peptides named glucagon-like peptide-1and glucose-dependent insulinotropic polypeptide. Incretin-based therapies have become a new class of antidiabetic drugs for its promising action on insulinotropic secretion and improving insulin receptor. Considering the fact which diabetes is a significant risk factor for most other age-related disease the extensive protective roles of incretin in chronic disease have being focused. Based on the evidence from animals where incretin protects against patholophysiology of neurodegenerative diseases, clinical trials for the treatment of AD and PD are currently ongoing. Moreover, the protective effect of incretin for heart has been observed in vascular smooth muscle cells, endothelial cells, and cardiac myocytes. Incretin is proven against atherosclerogenesis by inhibiting aortic vascular smooth muscle cells proliferation. It is also benefit for diabetic microvascular complications including nephropathy, retinopathy, and gastric ulcer. Furthermore, incretin can be used to treat NAFLD/NASH. Anti-tumoral properties of incretin have also been proven in ovarian cancer, pancreatic cancer, prostate cancer, and breast cancer.